Clinical trial programme
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

REPATHA®
APPROVED TO
REDUCE
CARDIOVASCULAR
RISK1

Clinical trial programme

Repatha® is being evaluated in PROFICIO – a comprehensive clinical trial programme involving a broad range of patients and clinical settings.2

  • 36 ongoing and completed clinical trials2
  • Over 38,000 patients2



*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; IVUS = Intravascular ultrasound; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; PROFICIO = Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
  2. Amgen Press Release. Available at: https://www.amgen.com/media/news-releases/2019/03/amgen-announces-new-fouryear-outcomes-study-to-examine-longterm-effects-of-repatha-evolocumab-in-highrisk-cardiovascular-disease-cvd-patients-without-prior-heart-attack-or-stroke/. Accessed: December 2019.
  3. Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD